Author Title [ Type(Desc)] Year
Filters: Author is Ponce, Doris M  [Clear All Filters]
Journal Article
Tamari R, Chung S, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales M-A, Ponce DM, Sauter CS, et al. CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and anti-thymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015.
Shah N, Dahi PB, Ponce DM, Sauter CS, Shaffer BC, Chung DJ, Politikos I, Lin RJ, Giralt SA, Papanicolaou G, et al. HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION. Transplant Cell Ther. 2021.
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales M-A, et al. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2021.
Brambilla CZuanelli, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, et al. Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplant Cell Ther. 2021.